Utrogestan in the Second Trimester: Safety & Benefits

Utrogestan (micronized progesterone) is commonly prescribed in the second trimester for specific indications.

Indications

  • History of preterm birth: Vaginal progesterone 200 mg nightly from 16–36 weeks reduces recurrent preterm birth (RCT evidence).
  • Short cervical length (<25 mm) on transvaginal ultrasound: Vaginal progesterone 200 mg nightly until 36 weeks.
  • Luteal phase support (IVF pregnancies): Continued until placental takeover (~10–12 weeks; sometimes extended).
  • Threatened preterm labor: Adjunct to tocolysis.

Route

  • Vaginal: Preferred; higher uterine concentration, fewer systemic side effects (drowsiness, dizziness).
  • Oral: Used if vaginal route not feasible; higher first-pass metabolism.

Safety

  • Progesterone is endogenous; micronized form is bioidentical.
  • No teratogenicity; large cohorts show no increase in congenital anomalies.
  • Side effects: vaginal discharge, irritation, drowsiness (oral), headache, breast tenderness.

Monitoring

  • Cervical length surveillance (if indicated).
  • Maternal symptoms; fetal growth scans per protocol.

Always follow your obstetrician's specific prescription. Do not self-medicate or discontinue without guidance.

Prescription Medications - Related Articles